Maternal and perinatal outcomes of pregnant women with SARS-CoV-2 infection at the time of birth in England: national cohort study.
COVID-19
birth
fetal death
neonatal outcome
obstetrics
preeclampsia
pregnancy
preterm birth
stillbirth
Journal
American journal of obstetrics and gynecology
ISSN: 1097-6868
Titre abrégé: Am J Obstet Gynecol
Pays: United States
ID NLM: 0370476
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
04
05
2021
revised:
13
05
2021
accepted:
14
05
2021
pubmed:
24
5
2021
medline:
23
11
2021
entrez:
23
5
2021
Statut:
ppublish
Résumé
Some studies have suggested that women with SARS-CoV-2 infection during pregnancy are at increased risk of adverse pregnancy and neonatal outcomes, but these associations are still not clear. This study aimed to determine the association between SARS-CoV-2 infection at the time of birth and maternal and perinatal outcomes. This is a population-based cohort study in England. The inclusion criteria were women with a recorded singleton birth between May 29, 2020, and January 31, 2021, in a national database of hospital admissions. Maternal and perinatal outcomes were compared between pregnant women with a laboratory-confirmed SARS-CoV-2 infection recorded in the birth episode and those without. Study outcomes were fetal death at or beyond 24 weeks' gestation (stillbirth), preterm birth (<37 weeks' gestation), small for gestational age infant (small for gestational age; birthweight at the <tenth centile), preeclampsia or eclampsia, induction of labor, mode of birth, specialist neonatal care, composite neonatal adverse outcome indicator, maternal and neonatal length of hospital stay after birth (3 days or more), and 28-day neonatal and 42-day maternal hospital readmission. Adjusted odds ratios and their 95% confidence interval for the association between SARS-CoV-2 infection status and outcomes were calculated using logistic regression, adjusting for maternal age, ethnicity, parity, preexisting diabetes mellitus, preexisting hypertension, and socioeconomic deprivation measured using the Index of Multiple Deprivation 2019. Models were fitted with robust standard errors to account for hospital-level clustering. The analysis of the neonatal outcomes was repeated for those born at term (≥37 weeks' gestation) because preterm birth has been reported to be more common in pregnant women with SARS-CoV-2 infection. The analysis included 342,080 women, of whom 3527 had laboratory-confirmed SARS-CoV-2 infection. Laboratory-confirmed SARS-CoV-2 infection was more common in women who were younger, of non-White ethnicity, primiparous, or residing in the most deprived areas or had comorbidities. Fetal death (adjusted odds ratio, 2.21; 95% confidence interval, 1.58-3.11; P<.001) and preterm birth (adjusted odds ratio, 2.17; 95% confidence interval, 1.96-2.42; P<.001) occurred more frequently in women with SARS-CoV-2 infection than those without. The risk of preeclampsia or eclampsia (adjusted odds ratio, 1.55; 95% confidence interval, 1.29-1.85; P<.001), birth by emergency cesarean delivery (adjusted odds ratio, 1.63; 95% confidence interval, 1.51-1.76; P<.001), and prolonged admission after birth (adjusted odds ratio, 1.57; 95% confidence interval, 1.44-1.72; P<.001) were significantly higher for women with SARS-CoV-2 infection than those without. There were no significant differences (P>.05) in the rate of other maternal outcomes. The risk of neonatal adverse outcome (adjusted odds ratio, 1.45; 95% confidence interval, 1.27-1.66; P<.001), need for specialist neonatal care (adjusted odds ratio, 1.24; 95% confidence interval, 1.02-1.51; P=.03), and prolonged neonatal admission after birth (adjusted odds ratio, 1.61; 95% confidence interval, 1.49-1.75; P<.001) were all significantly higher for infants with mothers with laboratory-confirmed SARS-CoV-2 infection. When the analysis was restricted to pregnancies delivered at term (≥37 weeks), there were no significant differences in neonatal adverse outcome (P=.78), need for specialist neonatal care after birth (P=.22), or neonatal readmission within 4 weeks of birth (P=.05). Neonates born at term to mothers with laboratory-confirmed SARS-CoV-2 infection were more likely to have prolonged admission after birth (21.1% compared with 14.6%; adjusted odds ratio, 1.61; 95% confidence interval, 1.49-1.75; P<.001). SARS-CoV-2 infection at the time of birth is associated with higher rates of fetal death, preterm birth, preeclampsia, and emergency cesarean delivery. There were no additional adverse neonatal outcomes, other than those related to preterm delivery. Pregnant women should be counseled regarding risks of SARS-CoV-2 infection and should be considered a priority for vaccination.
Sections du résumé
BACKGROUND
Some studies have suggested that women with SARS-CoV-2 infection during pregnancy are at increased risk of adverse pregnancy and neonatal outcomes, but these associations are still not clear.
OBJECTIVE
This study aimed to determine the association between SARS-CoV-2 infection at the time of birth and maternal and perinatal outcomes.
STUDY DESIGN
This is a population-based cohort study in England. The inclusion criteria were women with a recorded singleton birth between May 29, 2020, and January 31, 2021, in a national database of hospital admissions. Maternal and perinatal outcomes were compared between pregnant women with a laboratory-confirmed SARS-CoV-2 infection recorded in the birth episode and those without. Study outcomes were fetal death at or beyond 24 weeks' gestation (stillbirth), preterm birth (<37 weeks' gestation), small for gestational age infant (small for gestational age; birthweight at the <tenth centile), preeclampsia or eclampsia, induction of labor, mode of birth, specialist neonatal care, composite neonatal adverse outcome indicator, maternal and neonatal length of hospital stay after birth (3 days or more), and 28-day neonatal and 42-day maternal hospital readmission. Adjusted odds ratios and their 95% confidence interval for the association between SARS-CoV-2 infection status and outcomes were calculated using logistic regression, adjusting for maternal age, ethnicity, parity, preexisting diabetes mellitus, preexisting hypertension, and socioeconomic deprivation measured using the Index of Multiple Deprivation 2019. Models were fitted with robust standard errors to account for hospital-level clustering. The analysis of the neonatal outcomes was repeated for those born at term (≥37 weeks' gestation) because preterm birth has been reported to be more common in pregnant women with SARS-CoV-2 infection.
RESULTS
The analysis included 342,080 women, of whom 3527 had laboratory-confirmed SARS-CoV-2 infection. Laboratory-confirmed SARS-CoV-2 infection was more common in women who were younger, of non-White ethnicity, primiparous, or residing in the most deprived areas or had comorbidities. Fetal death (adjusted odds ratio, 2.21; 95% confidence interval, 1.58-3.11; P<.001) and preterm birth (adjusted odds ratio, 2.17; 95% confidence interval, 1.96-2.42; P<.001) occurred more frequently in women with SARS-CoV-2 infection than those without. The risk of preeclampsia or eclampsia (adjusted odds ratio, 1.55; 95% confidence interval, 1.29-1.85; P<.001), birth by emergency cesarean delivery (adjusted odds ratio, 1.63; 95% confidence interval, 1.51-1.76; P<.001), and prolonged admission after birth (adjusted odds ratio, 1.57; 95% confidence interval, 1.44-1.72; P<.001) were significantly higher for women with SARS-CoV-2 infection than those without. There were no significant differences (P>.05) in the rate of other maternal outcomes. The risk of neonatal adverse outcome (adjusted odds ratio, 1.45; 95% confidence interval, 1.27-1.66; P<.001), need for specialist neonatal care (adjusted odds ratio, 1.24; 95% confidence interval, 1.02-1.51; P=.03), and prolonged neonatal admission after birth (adjusted odds ratio, 1.61; 95% confidence interval, 1.49-1.75; P<.001) were all significantly higher for infants with mothers with laboratory-confirmed SARS-CoV-2 infection. When the analysis was restricted to pregnancies delivered at term (≥37 weeks), there were no significant differences in neonatal adverse outcome (P=.78), need for specialist neonatal care after birth (P=.22), or neonatal readmission within 4 weeks of birth (P=.05). Neonates born at term to mothers with laboratory-confirmed SARS-CoV-2 infection were more likely to have prolonged admission after birth (21.1% compared with 14.6%; adjusted odds ratio, 1.61; 95% confidence interval, 1.49-1.75; P<.001).
CONCLUSION
SARS-CoV-2 infection at the time of birth is associated with higher rates of fetal death, preterm birth, preeclampsia, and emergency cesarean delivery. There were no additional adverse neonatal outcomes, other than those related to preterm delivery. Pregnant women should be counseled regarding risks of SARS-CoV-2 infection and should be considered a priority for vaccination.
Identifiants
pubmed: 34023315
pii: S0002-9378(21)00565-2
doi: 10.1016/j.ajog.2021.05.016
pmc: PMC8135190
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
522.e1-522.e11Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Références
Ann Hum Biol. 2011 Jan;38(1):7-11
pubmed: 21175302
Am J Obstet Gynecol. 2007 Sep;197(3):223-8
pubmed: 17826400
JAMA. 2021 Jan 5;325(1):87-89
pubmed: 33284323
Ultrasound Obstet Gynecol. 2021 Apr;57(4):573-581
pubmed: 33620113
BMC Health Serv Res. 2006 Jun 15;6:77
pubmed: 16776836
Am J Obstet Gynecol. 2021 Apr;224(4):382.e1-382.e18
pubmed: 33091406
PLoS One. 2021 May 5;16(5):e0251123
pubmed: 33951100
BMJ. 2021 Mar 18;372:n628
pubmed: 33737413
Hypertension. 2020 Apr;75(4):918-926
pubmed: 32063058
JAMA Pediatr. 2021 Aug 1;175(8):817-826
pubmed: 33885740
J Clin Epidemiol. 2014 May;67(5):578-85
pubmed: 24411310
Arch Pathol Lab Med. 2021 May 1;145(5):517-528
pubmed: 33393592
JAMA. 2021 May 25;325(20):2076-2086
pubmed: 33914014
Arch Dis Child Fetal Neonatal Ed. 2019 Sep;104(5):F502-F509
pubmed: 30487299
Stat Med. 2011 Feb 20;30(4):377-99
pubmed: 21225900
Am J Perinatol. 2022 Jan;39(1):75-83
pubmed: 34598291
J Clin Med. 2020 Jun 29;9(7):
pubmed: 32610499
JAMA. 2021 May 18;325(19):2013-2014
pubmed: 33843975
Ultrasound Obstet Gynecol. 2021 May;57(5):681-686
pubmed: 33734524
Am J Obstet Gynecol. 2021 Sep;225(3):303.e1-303.e17
pubmed: 33775692
Ann Intern Med. 2021 Jun;174(6):873-875
pubmed: 33428442
JAMA. 2020 Jul 10;:
pubmed: 32648892
N Engl J Med. 2021 Jun 17;384(24):2273-2282
pubmed: 33882218
J Hosp Med. 2021 May;16(5):290-293
pubmed: 33617437
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Am J Obstet Gynecol. 2020 Jul;223(1):109.e1-109.e16
pubmed: 32360108
BMJ. 2020 Sep 1;370:m3320
pubmed: 32873575
Lancet. 2020 Sep 5;396(10252):e22
pubmed: 32861313
J Public Health (Oxf). 2012 Mar;34(1):138-48
pubmed: 21795302
Am J Obstet Gynecol. 2021 May;224(5):510.e1-510.e12
pubmed: 33221292
BJOG. 2014 Jan;121(2):183-92
pubmed: 24251861
Lancet Child Adolesc Health. 2021 Feb;5(2):113-121
pubmed: 33181124